HMS Holdings Corp. HMSY is well poised for growth on the back of growing Payment Integrity Solutions and Total Population Management, and strong margins. However, intense competition in the U.S. medical cost containment industry remains a concern.
The stock carries a Zacks Rank #3 (Hold).
Shares of HMS Holdings have gained 34.2%, outperforming the industry’s growth of 6.4% in a year’s time. The stock also outpaced the S&P 500 Index’s rally of 1.9%.
What’s Favoring the Stock?
HMS Holdings continues to benefit from its promising and growing Payment Integrity Solutions. Payment Integrity (PI) has been benefiting from greater throughput in the implementation process, expedited customer approvals for new PI edits, applied technology to simplify processes, increased coder productivity and accelerated revenue generation.
Per management, PI is anticipated to be a significant contributor to the Analytical Services wing in 2019.
Apart from PI solutions, Total Population Management (TPM) comes under HMS Holdings’ unique suite of Analytical Services. The company has been gaining traction from TPM for a signioficant period of time that has been contributing significantly to the company’s top line.
Product-yield enhancements and process improvements are consistently bolstering HMS Holdings’ margins and profitability. The company has been diligently managing operating expenses and broadening the use of technology tools such as robotic process automation and machine learning.
On the basis of these initiatives, the company has been exhibiting strong margins in the last few years and the momentum is expected to continue in the near term.
What’s Deterring the Stock?
The company faces intense competition in the U.S. medical cost containment space, which is a dynamic industry as customers have a lot of alternatives available to them.
Which Way Are Estimates Headed?
For 2019, the Zacks Consensus Estimate for revenues is pegged at $649.4 million, indicating an improvement of 8.5% from the year-ago period. The same for earnings stands at $1.20 per share, suggesting growth of 15.4% from the year-ago reported figure.
Some better-ranked stocks from the broader medical space are Cardiovascular Systems, Inc. CSII, Quidel Corporation QDEL and Heamonetics Corporation HAE, each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Cardiovascular Systems has earnings growth rate for fiscal fourth quarter of 2019 of 33.3%.
Quidel Corporation has a long-term earnings growth rate of 25%.
Heamonetics has a long-term earnings growth rate 13.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119%and +164%in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
HMS Holdings Corp (HMSY) : Free Stock Analysis Report
Cardiovascular Systems, Inc. (CSII) : Free Stock Analysis Report
Quidel Corporation (QDEL) : Free Stock Analysis Report
Haemonetics Corporation (HAE) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research